Bank Of Montreal Aeterna Zentaris Inc. Transaction History

Bank Of Montreal

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.17 - $0.37 $412 - $897	-2,426 Reduced 18.95%	10,373 $2,000
Q1 2022 May 12, 2022	BUY	$0.33 - $0.42 $887 - $1,129	2,690 Added 26.61%	12,799 $5,000
Q4 2021 Feb 11, 2022	SELL	$0.36 - $0.77 $28 - $61	-80 Reduced 0.79%	10,109 $4,000
Q3 2021 Nov 12, 2021	SELL	$0.59 - $0.88 $3,980 - $5,937	-6,747 Reduced 39.84%	10,189 $7,000
Q2 2021 Aug 12, 2021	BUY	$0.83 - $1.14 $14,056 - $19,307	16,936 New	16,936 $15,000

Ticker AEZS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,855,880
Market Cap $19.4M
Description
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult grow...

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

Stay updated on Bank Of Montreal with notifications on news.